Introduction Lung and colorectal cancers are among the toughest cancers to treat globally. A major challenge in these cancers is a genetic mutation called KRAS G12C — long considered “undruggable.” But recent breakthroughs have made targeted treatment possible. One of the most promising advancements is the combination of Krazati + Cetuximab, which delivers stronger and …
Introduction Cancer treatment has advanced dramatically in the past decades. Rather than relying on traditional chemotherapy – which indiscriminately kills rapidly dividing cells – new drugs target specific molecular pathways that tumor cells use to survive, grow, invade, and evade the immune system. One of the most promising innovations in this field is zanzalintinib, a …
Elahere (mirvetuximab soravatansine-ginx) is a pioneering antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer, particularly in patients whose tumors express FRα (folate receptor-alpha). While this breakthrough therapy offers new hope, it also addresses some important safety concerns. This detailed guide explains the Elahere side effects , their frequency, severity, why they occur, how to monitor …
Introduction The field of oncology has evolved dramatically in recent years, with the introduction of targeted therapies that offer improved outcomes with fewer side effects. Among these revolutionary therapeutic agents, pirtobrutinib stands out as a next-generation Bruton tyrosine kinase (BTK) inhibitor that offers new hope for patients battling advanced B-cell malignancies. The pirtobrutinib approval has …
Epcoritamab – an advanced immunotherapy used in certain B-cell lymphomas – offers hope to many patients. But like many powerful treatments, it has a spectrum of side effects. Fully understanding the Epcoritamab Side Effects can help patients and caregivers stay informed, respond promptly to concerns, and increase safety while getting the most out of therapy. …
What is Lurbinectedin? Lurbinectedin is an innovative anticancer drug primarily used to treat metastatic small cell lung cancer (SCLC) in adults who have received platinum-based chemotherapy. SCLC is known to be the most aggressive and rapidly spreading lung cancer, with a high recurrence rate and very few effective second-line treatments. Due to this therapeutic gap, …
Pivekimab Sunirine – A Complete 2025 Guide for Pharmacy Students & Healthcare Professionals Pivekimab Sunirin is one of the most advanced targeted therapies developed for hematologic malignancies, particularly relapsed or refractory acute leukemia. As oncology evolves rapidly, this drug has attracted attention due to its unique mechanism of action, CD123 specificity, and promising clinical activity …
Introduction: A New Era of Cancer Treatment (SEO-Optimized) The best new oncology drugs approved by FDA in 2024–25 represent some of the biggest milestones in cancer therapy—especially for pharmacy students, clinicians, researchers, and competitive exam aspirants. Cancer treatment is rapidly evolving with next-gen immunotherapies, targeted therapies, bispecific antibodies, ADCs (antibody–drug conjugates), and precision medicines leading …
The year 2025 marked a significant milestone in cancer treatment, redefining how physicians approach immune-based therapies. With the approval of several Next Gen Immunotherapy Approved in 2025, the oncology landscape shifted toward more precise, accessible, and patient-friendly interventions. These innovations go beyond first-generation immunotherapies (such as classic checkpoint inhibitors) and introduce improved cell therapies, bispecific …
Introduction Belzutifan, marketed under the brand name Velireg, has emerged as a promising drug in the fight against certain types of cancer, particularly renal cell carcinoma (RCC) and tumors associated with von Hippel-Lindau (VHL) disease. While its benefits in slowing tumor growth are significant, understanding the side effects of belzutifan is equally important to ensure …
